Showing results (401-410 of 454) with videos related to
Sort By:
Pageof 46
NPJ Breast Cancer|September 8, 2023
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancerAlessandra Fabi, Luisa Carbognin, Andrea Botticelli, et al.Current Pharmaceutical Design|October 25, 2012
Hsp60, a novel target for antitumor therapy: structure-function features and prospective drugs designAndrea Pace, Giampaolo Barone, Antonino Lauria, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 25, 2026
Mapping integrated care for brain tumour-related epilepsy in the Italian RIN-IRCCS networkElena Anghileri, Alessia Marcassoli, Veronica Villani, et al.Frontiers in Oncology|July 13, 2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative studyAgnese Fabbri, Fabrizio Nelli, Andrea Botticelli, et al.Future Oncology (London, England)|June 14, 2025
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK studyFranco Antonio, Luisa Carbognin, Ida Paris, et al.Cancers|October 14, 2022
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-MakingFrancesco Pavese, Ettore Domenico Capoluongo, Margherita Muratore, et al.Cancers|April 23, 2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus ReviewMattia Garutti, Gaia Griguolo, Andrea Botticelli, et al.Journal of the National Cancer Institute|March 28, 2026
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid TumorsGiovanni Maria Iannantuono, Stefano Sganga, Tommaso Giovagnoli, et al.Breast Cancer Research and Treatment|March 30, 2017
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Alessandra Fabi, Luca Moscetti, et al.Breast Cancer Research : BCR|October 29, 2022
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER studyNicla La Verde, Giovanna Damia, Ornella Garrone, et al.Pageof 46